Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NYX-783 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).”In the company’s words, NCT04044664 on ClinicalTrials.gov
- Tested for
- PTSD, Post-Traumatic Stress Disorder
- Main trialPhase 2/3
- “A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants with Post-Traumatic Stress Disorder (PTSD)”In the company’s words, NCT05181995 on ClinicalTrials.gov
Other drugs for PTSD
- MethyloneTranscend Therapeutics · Phase 3
- PsilocybinCOMPASS Pathways · Phase 2/3
- Inhaled isofluraneSedana Medical · Phase 3
- MDMARemedy · Phase 2
- HB-1HB BioTech, LLC · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Terminated | 30 Mar 2023 | Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD | |
| Phase 2Completed | 5 Aug 2020 | Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026